Physician profile
Ann Makar
NPI 1043697162
$8,395.97
in general payments reported to CMS, 2019-2025
25 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 90% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $61.85 · 2021: $850 · 2022: $2,027 · 2023: $1,940 · 2024: $2,056 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,452 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,451.52 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $865.87 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $847.59 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $792.60 | 2021-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $779.19 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $676.30 | 2020-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $651.69 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $623.25 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $579.62 | 2021-2025 | Ingrezza |
| Corium, LLC | $474.80 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $426.21 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $263.54 | 2022-2025 | Gralise, Loreev Xr |
| Axsome Therapeutics, INC. | $236.42 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $223.84 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $205.48 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $182.49 | 2022-2024 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $105.25 | 2021-2025 | Xelstrym |
| Bausch Health US, LLC | $98.18 | 2022-2024 | Aplenzin, Wellbutrin |
| Avanir Pharmaceuticals, INC. | $80.81 | 2022 | |
| Jazz Pharmaceuticals INC. | $70.68 | 2021-2022 | |
| Tris Pharma INC | $68.98 | 2022-2025 | Dyanavel Xr |
| Alfasigma USA, INC. | $58.93 | 2021-2022 | |
| Abbvie INC. | $39.12 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $18.55 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $14.31 | 2021 | |
| Lilly USA, LLC | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Makar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.